4basebio
- Zoe Whiffen
Zoe Whiffen has extensive experience in the biopharmaceutical industry, currently serving as the Director of Manufacturing Science & Technology at 4basebio since October 2020. Previous roles at 4basebio include Head of Manufacturing Science and Technology and Manufacturing Science and Technology team lead, as well as a position as a Research Associate. Prior to that, Zoe worked at LGC as a Large Molecule Bioanalysis scientist from September 2018 to October 2020 and as a Student Scientist from July 2016 to July 2017. Additionally, Zoe gained international experience during a Leonardo da Vinci training placement with the European Civil Platform on Lifelong Learning in July 2013. Earlier in their career, Zoe was a Snowboarding Instructor at John Nike Leisuresport Limited from July 2010 to September 2012. Zoe earned a BSc in Biochemistry with a Year in Industry from the University of York between 2014 and 2018.
Org chart
Upgrade to view 5 reports
Offices
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.
